Premier Health Plan considers Negative Pressure Wound Therapy (NPWT) in the home setting medically necessary for the following indications:

Similar documents
Negative Pressure Wound Therapy (NPWT)

Topical Oxygen Wound Therapy (MEDICAID)

Negative Pressure Wound Therapy

See Policy CPT/HCPCS CODE section below for any prior authorization requirements

Negative Pressure Wound Therapy Pumps

Durable Medical Equipment Providers

MP.094.MH Transcutaneous Electrical Nerve Stimulators

POLICIES AND PROCEDURE MANUAL

Clinical Policy Title: Vacuum assisted closure in surgical wounds

Premier Health Plan considers Oral Appliances for Obstructive Sleep Apnea (OSA) medically necessary for the following indications:

MedStar Health considers Continuous Home Pulse Oximetry medically necessary for the following indications:

Premier Health Plan considers Iontophoresis for Musculoskeletal Conditions medically necessary for the following indications:

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL Policy Number: PA.010.MH Last Review Date: 05/11/2017 Effective Date: 07/01/2017

MedStar Health considers External Counterpulsation Therapy (ECP) medically necessary for the following indications:

Itamar Medical 2016 Reimbursement Coding Guide

NEGATIVE PRESURE WOUND THERAPY PROGRAM

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL Policy Number: MP.103.MH Last Review Date: 11/08/2018 Effective Date: 02/01/2019

Premier Health Plan considers Intravascular Ultrasound (IVUS) for Coronary Vessels medically necessary for the following indications:

MedStar Health considers Cough Assist Devices medically necessary for the following indications:

Medical Policy Original Effective Date: 01/23/2019

MP.090.MH Nerve Block, Paravertebral, Facet Joint, and SI Injections

Corporate Medical Policy

First Coast Service Options (FCSO) Medicare Policy Primer

Negative Pressure Wound Therapy (NPWT) (Vacuum-Assisted Wound Closure)

o Venous edema o Stasis ulcers o Varicose veins (not including spider veins) o Lipodermatosclerosis

Clinical Policy Title: Vacuum assisted closure in surgical wounds

Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145

Clinical Policy: Low-Frequency Ultrasound Therapy for Wound Management Reference Number: CP.MP.139 Last Review Date: 01/18

RESPIRATORY ASSIST DEVICE E0471

Coverage Summary. Wound Treatments

VACUUM ASSISTED CLOSURE (V.A.C.) THERAPY: Mr. Ismazizi Zaharudin Jabatan pembedahan Am Hospital Kuala Lumpur

Clinical Policy: Digital Breast Tomosynthesis Reference Number: CP.MP.90

PNEUMATIC COMPRESSION DEVICES IN THE HOME SETTING

Disclosures. Outpatient NPWT Options Free up Hospital Beds, but Do They Work? Objectives. Clinically Effective: Does it Work?

CERT Oxygen Errors: The DME CERT Outreach and Education Task Force Responds

V.A.C. Therapy Patient Guide. Are you suffering from a wound? Ask your doctor about V.A.C. Therapy and whether it may be right for you.

Oxygen and Oxygen Equipment

Blepharoptosis repair is covered as functional/reconstructive surgery to correct: Visual impairment due to droop or displacement of the upper lid.

and Supplies Amended Date: November 1, 2016 Table of Contents

RESPIRATORY ASSIST DEVICE E0471

Determining Wound Diagnosis and Documentation Tips Job Aid

Reimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Procedures 1 Performed by Emergency Medicine Physicians

Clinical Policy: Oxygen Therapy in the Home Reference Number: CP.MP.485

RESPIRATORY ASSIST DEVICE E0470

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Oxygen and Oxygen Equipment

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Atezolizumab (Tecentriq) Reference Number: CP.PHAR.235 Effective Date: 06/16 Last Review Date: 05/17

Cahaba Medicare Policy Primer 1,2 for Apligraf

Clinical Policy: Total Artificial Heart Reference Number: CP.MP.127

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119

CERT PAP Errors: The DME CERT Outreach and Education Task Force Responds

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18

Clinical Policy: Aflibercept (Eylea) Reference Number: CP.PHAR.184

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.

Respiratory Assist Device E0470:

Clinical Policy: Fecal Calprotectin Assay Reference Number: CP.MP.135

MedStar Health considers Septoplasty-Rhinoplasty medically necessary for the following indications:

Surgical Preparation Codes for Skin Replacement Surgery** Hospital Outpatient/Ambulatory Surgical Center Setting

Clinical Policy: Trabectedin (Yondelis) Reference Number: CP.PHAR.204 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Fluticasone/Salmeterol (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 08/16 Last Review Date: 08/17

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Levetiracetam (Spritam) Reference Number: CP.CPA.156 Effective Date: Last Review Date: 11.18

See Important Reminder at the end of this policy for important regulatory and legal information.

1/5. Introduction. Primary endpoint Time to reach readiness for closure by surgical intervention or left for closure by secondary intention

Clinical Policy: Mifepristone (Korlym) Reference Number: CP.PHAR.101

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

Oxygen and Oxygen Equipment

Medicare CPAP/BIPAP Coverage Criteria

Sympathetic Electrical Stimulation Therapy for Chronic Pain

See Important Reminder at the end of this policy for important regulatory and legal information.

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL Policy Number: PA.017.MH Last Review Date: 08/04/2016 Effective Date: 01/01/2016

See Important Reminder at the end of this policy for important regulatory and legal information.

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

Electrical Stimulation Device Used for Cancer Treatment

The Use of the. in Clinical Practice

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea

Diabetes Management, Equipment and Supplies

Wound & Burn. Reimbursement & Coding Guide

Glucose Monitors and Supplies

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Ustekinumab (Stelara) Reference Number: CP.PHAR.264

Medical Necessity Guidelines: Applied Behavioral Analysis (ABA) including Early Intervention for RITogether

Novitas Medicare Policy Primer

See Important Reminder at the end of this policy for important regulatory and legal information.

V.A.C. Therapy Safety Information

Vacuumed Assisted Closure

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Dabrafenib (Tafinlar) Reference Number: CP.PHAR.239 Effective Date: 07/16 Last Review Date: 07/17 Line of Business: Medicaid

Product Name or Headline

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL Policy Number: MP.066.MH Last Review Date: 11/08/2018 Effective Date: 01/01/2019

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19

See Important Reminder at the end of this policy for important regulatory and legal information.

Transcription:

Premier Health Plan POLICY AND PROCEDURE MANUAL PA.009.PH Negative Pressure Wound Therapy This policy applies to the following lines of business: Premier Commercial Premier Employee Premier Health Plan considers Negative Pressure Wound Therapy (NPWT) in the home setting medically necessary for the following indications: 1. The member has one of the following ulcer types: Chronic Stage III or IV pressure ulcer Neuropathic ulcer (i.e., diabetic) Venous or arterial insufficiency ulcer Chronic ulcer of mixed etiology (present for at least 30 days). 2. A complete wound therapy program (described below) was tried and failed or considered and contraindicated prior to application of NPWT Complete Wound Therapy Program: 1. For all Ulcers or Wounds: The following components of a wound therapy program must include all of the following general measures, which should be addressed, applied, or considered and ruled out prior to application of NPWT: Documentation of evaluation, care, and wound measurements by a licensed medical professional Dressings have been applied to maintain a moist wound environment Debridement of necrotic tissue if present, Evaluation of and provision for adequate nutritional status additionally For Stage III or IV Pressure Ulcers: Member has been appropriately turned and positioned

The member has used a group 2 or 3 support surface for pressure ulcers on the posterior trunk or pelvis (Refer to policy PA.028 Pressure Reducing Support Surfaces-Groups 1, 2, & 3) The member s moisture and incontinence have been appropriately managed 2. For Neuropathic Ulcers (i.e., diabetic) All of the following components must be part of a complete wound therapy program for this type of ulcer: o The member has been on a comprehensive diabetic management program o Reduction in pressure on a foot ulcer has been accomplished with appropriate modalities 3. For Venous Insufficiency Ulcers All of the following components must be part of a complete wound therapy program for this type of ulcer: o Compression bandages and/or garments have been consistently applied o Leg elevation and ambulation have been encouraged. Ulcers and Wounds Encountered in an Inpatient Setting: 1. An ulcer or wound (as described above under home setting) is encountered in the inpatient setting, or either one of the following acute wounds occurs: Complications of a surgically created wound (for example, dehiscence) Or A traumatic wound (i.e., pre-operative flap or graft) where there is documentation of the medical necessity for accelerated formation of granulation tissue which cannot be achieved by other available topical wound treatments (i.e., comorbidities that will not allow for healing times achievable with other topical wound treatments). 2. Wound treatments (as described above under home setting) have been tried or considered and ruled out 3. The treating physician has determined that NPWT is needed because it is considered to be the best available treatment option. Page 2 of 6

4. Treatment is ordered to continue beyond discharge in the home setting Continuation of NPWT For continued coverage of the pump and supplies for all wounds and ulcers described in the policy, a licensed medical professional must do all of the following: 1. On a regular basis, Directly assess the wound(s) being treated with the NPWT pump Supervise or directly perform the NPWT dressing changes 2. On at least a monthly basis, document changes in the ulcer s dimensions and characteristics. Requirements of NPWT 1. The NPWT device should be Food and Drug Administration (FDA) approved for the age of the member 2. Only one NPWT device is allowed per member for the same time period 3. The NPWT pumps must be capable of accommodating more than one wound dressing set for multiple wounds on a member. 4. Coverage for NPWT is provided up to a maximum of 15 dressing kits (A6550) per wound per month. 5. Coverage for NPWT is provided up to a maximum of ten canister sets (A7000) per month unless there is documentation evidencing a large volume of drainage (greater than 90 ml of exudate per day) 6. For high volume exudative wounds, a stationary pump with the largest capacity canister should be used. 7. Suppliers must verify with the ordering physicians any changed or atypical utilization. Refills and Recurring Supplies/Items 1. Suppliers must not deliver refills without a written refill request from a beneficiary 2. Suppliers must contact the member prior to dispensing the refill and not automatically ship on a pre-determined basis, even if authorized by the member 3. Contact with the member or designee regarding refills must take place no sooner than 14 calendar days prior to the delivery/shipping date 4. A supplier must not dispense more than a one month quantity at a time, regardless of utilization Page 3 of 6

5. For delivery of refills, the supplier must deliver the supplies/items no sooner than ten calendar days prior to the end of usage for the current product. This is regardless of which delivery method is utilized 6. Suppliers are required to have contact with the beneficiary or caregiver/designee prior to dispensing a new supply of items 7. Suppliers must not dispense a quantity of supplies exceeding a beneficiary's expected utilization Limitations Discontinuation of NPWT For all wounds and ulcers described in this policy, NPWT is considered not medically necessary and will be discontinued for any of the following reasons: 1. Criteria for continuation of NPWT (listed above) has not been met 2. Adequate wound healing has taken place 3. A measurable degree of wound healing has not occurred over a four week period 4. A period of four months has elapsed since initiation of NPWT. The medical necessity of NPWT beyond four months will be given individual consideration based upon required additional documentation 5. Equipment and/or supplies are no longer being used for the member (whether or not by the physician s order) Other reasons not medically necessary: NPWT is considered not medically necessary and therefore not covered for any the following conditions: 1. The presence of necrotic tissue with eschar (if debridement has not been attempted.) 2. Osteomyelitis within the vicinity of the wound and is not concurrently being treated with intent to cure 3. A cancer in the wound 4. The presence of a fistula connecting to an organ or body cavity within the vicinity of the wound See Also: PA.010.PH Durable Medical Equipment, Corrective Appliances and Other Devices; Repair/Replacement Background Negative Pressure Wound Therapy (NPWT) is defined as the application of subatmospheric pressure to a wound to remove exudate and debris from wounds. NPWT is delivered through an integrated system of a suction pump, separate exudate collection Page 4 of 6

chamber and dressing sets to a qualified wound. In these systems, exudate is completely removed from the wound site to the collection chamber Codes: CPT/ HCPCS Codes Code A6550 E2402 Description Wound care set, for negative pressure wound therapy electrical pump, includes all supplies and accessories Negative pressure wound therapy electrical pump, stationary or portable References 1. American Diabetes Association: Diabetes Medical Management Plan. 1995-2013. Last edited: February 20, 2015. http://www.diabetes.org/living-withdiabetes/parents-and-kids/diabetes-care-at-school/written-care-plans/diabetesmedical-management.html 2. Centers for Medicare and Medicaid Services (CMS). Local coverage Determination (LCD) No. L33821. Negative-Pressure Wound Therapy Pumps. (Contractor: National Government Services, Inc.). Revision Effective Date: 10/01/2015. https://www.cms.gov/medicare-coverage-database/details/lcddetails.aspx?lcdid=33821&contrid=138&ver=4&contrver=1&coverageselectio n=both&articletype=all&policytype=final&s=ohio&keyword=negative+pressur e+wound+therapy&keywordlookup=title&keywordsearchtype=&bc=gaa AABAAAAAAAA%3d%3d& 3. Centers for Medicare and Medicaid Services (CMS): Medicare Learning Network MLN No. SE1222. Negative Pressure Wound Therapy Interpretive Guidelines. Posted 2011. http://www.cms.gov/outreach-and-education/medicare-learning- Network-MLN/MLNMattersArticles/Downloads/SE1222.pdf 4. Hayes Medical Technology Directory. Negative Pressure Wound Therapy for Postsurgical Mediastinitis. Publication Date: March 12, 2015 5. Hayes Medical Technology Directory. Negative Pressure Wound Therapy in the Adjunct Treatment of Skin Grafts. Publication Date: June 25, 2015 6. Hayes Medical Technology Directory. Negative Pressure Wound Therapy for Wounds Other than Sternal Wounds and Skin Grafts. Annual Review: July 20, 2015. 4. National Pressure Ulcer Advisory Panel (NPUAP): Pressure Ulcer Category/Staging Illustrations. Accessed: 09/03/2015. Page 5 of 6

http://www.npuap.org/resources/educational-and-clinical-resources/pressureulcer-categorystaging-illustrations/ Disclaimer: Premier Health Plan medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Premier Health Plan and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Premier Health Plan reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations. These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited. Page 6 of 6